Zelira in the news
Articles
For media related enquiries please contact Damien Carbon at Profile Media
Ph: +61 (0) 412 332 122 E: damienc@profilemedia.com.au
The Market Herald – Zelira Therapeutics (ASX:ZLD) confirms ZTL-103 is safe and well-tolerated
Zelira Therapeutics (ZLD) has confirmed its phase one dose-escalation trial of ZTL-103 has successfully met its primary and secondary endpoints for safety and efficacy.
The study was conducted at the St Vincent’s Hospital in Melbourne, as well as Emerald Clinics (EMD) in Perth.
The Market Herald – Zelira Therapeutics (ASX:ZLD) confirms ZTL-103 is safe and well-tolerated